Zydus Cadila Strides Ahead With NASH Filing In India
API Manufacturing Unit In Dabhasa Receives NAI
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
You may also be interested in...
Zydus Cadila’s launch of the world’s first biosimilar to Roche’s breast cancer drug Kadcyla in India at an 80% discount to the original's listed price is expected to improve access, and follows its pioneering launch of an adalimumab biosimilar and a NASH therapy
Cadila is exploring orphan indications for saroglitazar magnesium, in addition to the approaching Phase III NASH clinical trials for its lead NCE. Meanwhile, it counts on new product launches and biosimilars to take its FY21 growth story ahead.
Atypical histological findings from a Phase IIb NASH study lead CymaBay to terminate mid-stage studies in NASH and PSC and place a Phase III PBC trial on hold.